| Symbol | ENDV |
|---|---|
| Name | ENDONOVO THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 91367 United States CA 6320 Canoga Avenue 15th Floor |
| Telephone | +1 3104869146 |
| Fax | — |
| — | |
| Website | http://www.endonovo.com |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | UNAUDITED |
| Reporting Status | Alternative Reporting Standard |
| CIK | 0001528172 |
| Description | Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovos Electroceutical Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovos Electroceutical Therapy has CMS National Coverage for the treatment of chronic wounds. The Companys current pipeline of clinical-stage Electroceutical Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis. Additional info from OTC: |
No news found.